Prevalence of pretreatment HIV resistance to integrase inhibitors in West African and Southeast Asian countries.

Autor:	Aghokeng AF; MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France., Ngo-Giang-Huong N; MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.; LMI Presto, IRD-Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand., Huynh THK; HIV/AIDS Laboratory, Pasteur Institute, Ho Chi Minh City, Vietnam., Dagnra AY; Faculté des Sciences de la Santé, Centre de Biologie Moléculaire et d'Immunologie, Université de Lomé, Lomé, Togo., D'Aquin Toni T; Programme PACCI, Virology Laboratory CIRBA, Abidjan, Côte d'Ivoire., Maiga AI; UCRC/SEREFO, FMOS, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali., Dramane K; Department of Biomedical Sciences, Virology Laboratory, Centre MURAZ, Bobo-Dioulasso, Burkina Faso., Eymard-Duvernay S; IRD, UMR MoISA, Montpellier Interdisciplinary Center on Sustainable Agri-food Systems, Montpellier, France., Chaix ML; INSERM U941, Université Paris Diderot, AP-HP, Hôpital Saint-Louis, Laboratoire de Virologie, Paris, France., Calvez V; Department of Virology, AP-HP, Hôpital Pitié Salpêtrière, Laboratoire de Virologie, Paris, F-75013, France., Descamps D; IAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité et INSERM, AP-HP, Hôpital Bichat, Paris, France.
Jazyk:	angličtina
Zdroj:	The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2024 May 02; Vol. 79 (5), pp. 1164-1168.
DOI:	10.1093/jac/dkae087
Abstrakt:	Objectives: Integrase strand transfer inhibitors (INSTIs) have been recently recommended as the preferred first-line option for antiretroviral treatment initiators in low- and middle-income countries (LMICs) in response to the growing circulation of resistant HIV to non-nucleoside reverse transcriptase inhibitors (NNRTIs). In this study, we estimated the frequency of pretreatment drug resistance (PDR) to INSTIs in West Africa and Southeast Asia. Materials and Methods: Using samples collected from 2015 to 2016, and previously used to assessed PI, NRTI and NNRTI resistance, we generated HIV integrase sequences and identified relevant INSTI PDR mutations using the Stanford and ANRS algorithms. Results: We generated 353 integrase sequences. INSTI PDR frequency was low, 1.1% (4/353) overall, ranging from 0% to 6.3% according to country. However, frequency of PDR to any drug class was very high, 17.9% (95% CI: 13.9%-22.3%), and mostly associated with a high level of NNRTI PDR, 9.7%, and a moderate level of NRTI PDR, 5.3%. Conclusions: Our results support the recent introduction of INSTIs in LMICs to improve treatment outcome in these settings, but also stress the need for effective actions to prevent uncontrolled emergence of drug resistance to this drug class. (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu